This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
De Wel et al. prospectively studied 24 patients with autosomal recessive limb-girdle muscular dystrophy type 12 (LGMDR12). Patients with LGMDR12 had no appreciable clinical worsening over a 2-year period according to repeated standardized clinical assessments, such as the 6-minute walk distance, 10-meter walk test, or Medical Research Council sum scores of muscle power. However, for patients with LGMDR12 and intermediate-stage fatty replacement of muscle tissue (20%–70% proton density fat fraction), there was a significant worsening of Biodex Isometric Dynamometry even after 1 year. The investigators conclude this quantitative tool may be useful in monitoring clinical progression and response to targeted treatments for LGMDR12. Dr. Kawada expresses a concern regarding lead-time bias in the cohort (unclear time of disease onset in a recessive condition) which may have confounded any differences in the various qualitative and quantitative assessments over time. In response, the investigators confirmed that patients were included at the time of clinical symptom onset. Both investigators agree that sex-related differences in disease progression are less well understood, and additional studies are suggested to explore reasons for the variability in prognosis between sexes and age groups.
De Wel et al. prospectively studied 24 patients with autosomal recessive limb-girdle muscular dystrophy type 12 (LGMDR12). Patients with LGMDR12 had no appreciable clinical worsening over a 2-year period according to repeated standardized clinical assessments, such as the 6-minute walk distance, 10-meter walk test, or Medical Research Council sum scores of muscle power. However, for patients with LGMDR12 and intermediate-stage fatty replacement of muscle tissue (20%–70% proton density fat fraction), there was a significant worsening of Biodex Isometric Dynamometry even after 1 year. The investigators conclude this quantitative tool may be useful in monitoring clinical progression and response to targeted treatments for LGMDR12. Dr. Kawada expresses a concern regarding lead-time bias in the cohort (unclear time of disease onset in a recessive condition) which may have confounded any differences in the various qualitative and quantitative assessments over time. In response, the investigators confirmed that patients were included at the time of clinical symptom onset. Both investigators agree that sex-related differences in disease progression are less well understood, and additional studies are suggested to explore reasons for the variability in prognosis between sexes and age groups.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Received December 14, 2022.
- Accepted in final form December 14, 2022.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
